Company Overview and News

 
Kirloskar Pneumatic gains 3% as co fixes record date for stock split

2018-09-17 moneycontrol
Shares of Kirloskar Pneumatic Company added 3 percent intraday Monday as company fixed September 27 as share-split record date.
505283 KIRLPNU

 
An evening walk down Dalal Street: Global cues lift Sensex 277 pts ahead of Q1FY19 earnings

2018-07-09 moneycontrol
Equity benchmarks began the week on a strong note on Monday, gaining over 0.70 percent on positive global cues and ahead of June quarter earnings. Banks and metals stocks, and Reliance Industries, L&T and Infosys drove the market higher.
DB 500325 500820 JIPKY RELIANCE KTKBANK 532538 ASIANPAINT 532187 505283 RIGD UCLQY 500493 BHARATFORG RLNIY YESBANK INDUSINDBK KIRLPNU JPASSOCIAT UCLQF 532648 YYBKY STRTECH ULTRACEMCO 532532 SRLRY 532652 532374

 
Kirloskar Pneumatic surges 8% as board to consider stock split

2018-07-09 moneycontrol
Share price of Kirloskar Pneumatic Company surged 8 percent intraday Monday as company to consider stock split on July 24.
505283 KIRLPNU

14
Axis Bank, YES Bank, SBI Life results

2018-04-25 thehindubusinessline
Thursday will see a host of prominent companies, such as AB Money, Accelya Kale, AU Small Finance, Automotive Stamplings, Axis Bank, Biocon, Coromandel Engineering, Essel Propack, HIL, Indian Energy Exchange, JL Morison, Kirloskar Pneumatic, Oil Country, Rallis India, Reliance Capital, SBI Life Insurance, Shriram City Union Finance, Supreme Industries, Tata Elxsi, Tata Metaliks and YES Bank declaring their quarter and full-year results for the period ended March 2018.
500408 RALLIS 532215 SPMWY 505283 SHRIRAMCIT AXISBANK SUPREMEIND 500355 500135 500111 YESBANK AXB RELCAPITAL TATAMETALI ESSELPRO KIRLPNU 513434 532648 YYBKY 533167 COROENGG AXBKY 532498 AXBA STS TATAELXSI 509930

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...